Pulse Biosciences CS (PLSE)

$21.57 +0.27 (1.27%)
Market Cap 1.45B
Revenue (ttm) 350,000.00
Net Income (ttm) -72.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20,794.29%
Debt to Equity Ratio 0.00
Volume 425,400
Avg Vol 353,990
Day's Range N/A - N/A
Shares Out 67.99M
Stochastic %K 77%
Beta 1.74
Analysts Strong Sell
Price Target $30.00

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 510-906-4600
Address:
601 Brickell Key Drive, Suite 1080, Miami, United States
TruthBroker2
TruthBroker2 Mar. 13 at 4:21 PM
$PLSE
0 · Reply
TruthBroker2
TruthBroker2 Mar. 13 at 1:30 PM
$SMMT $PLSE
0 · Reply
LeisureSuitLarry
LeisureSuitLarry Mar. 12 at 4:53 PM
$PLSE
0 · Reply
BubbaHoTep
BubbaHoTep Mar. 12 at 3:42 PM
$PLSE happening
0 · Reply
TruthBroker2
TruthBroker2 Mar. 12 at 2:52 PM
$PLSE We got a runner. HE KNOWS. Team Pulse
0 · Reply
bob2013
bob2013 Mar. 12 at 12:14 PM
$PLSE our mission to rigorously generate data and demonstrate the potential to improve patient outcomes and provide clinicians with more precise, tissue-sparing tools for minimally invasive treatment applications.” (HE KNOWS)!!!
0 · Reply
DARKP00L
DARKP00L Mar. 12 at 11:07 AM
$PLSE 07:06 on Mar. 12 2026 Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 12 at 11:00 AM
$PLSE Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
0 · Reply
TruthBroker2
TruthBroker2 Mar. 10 at 6:56 PM
$PLSE
0 · Reply
TruthBroker2
TruthBroker2 Mar. 10 at 3:50 PM
$PLSE Team Pulse
0 · Reply
Latest News on PLSE
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Mar 12, 2026, 7:00 AM EDT - 1 day ago

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Mar 9, 2026, 7:00 AM EDT - 4 days ago

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Mar 5, 2026, 7:00 AM EST - 8 days ago

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

Mar 4, 2026, 7:00 AM EST - 9 days ago

Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:05 PM EST - 21 days ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 20, 2026, 7:00 AM EST - 21 days ago

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Feb 20, 2026, 2:54 AM EST - 21 days ago

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

Feb 19, 2026, 4:05 PM EST - 22 days ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

What's Going With Pulse Biosciences Stock On Monday?

Feb 9, 2026, 9:18 AM EST - 4 weeks ago

What's Going With Pulse Biosciences Stock On Monday?

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Feb 5, 2026, 7:00 PM EST - 5 weeks ago

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Feb 4, 2026, 4:05 PM EST - 5 weeks ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

Feb 3, 2026, 7:00 AM EST - 5 weeks ago

Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 1:46 AM EST - 2 months ago

Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Jan 9, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Jan 6, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:05 PM EST - 2 months ago

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Dec 18, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Dec 9, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Nov 6, 2025, 4:05 PM EST - 4 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 11:01 PM EST - 4 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 4 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 24, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 22, 2025, 4:05 PM EDT - 5 months ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 10, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:06 PM EDT - 7 months ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Aug 1, 2025, 7:00 AM EDT - 8 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Jul 29, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:02 PM EDT - 10 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 6, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

May 1, 2025, 7:00 AM EDT - 11 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 24, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:46 PM EDT - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Mar 7, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Feb 4, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 30, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 21, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 10, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 9:00 AM EST - 1 year ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

TruthBroker2
TruthBroker2 Mar. 13 at 4:21 PM
$PLSE
0 · Reply
TruthBroker2
TruthBroker2 Mar. 13 at 1:30 PM
$SMMT $PLSE
0 · Reply
LeisureSuitLarry
LeisureSuitLarry Mar. 12 at 4:53 PM
$PLSE
0 · Reply
BubbaHoTep
BubbaHoTep Mar. 12 at 3:42 PM
$PLSE happening
0 · Reply
TruthBroker2
TruthBroker2 Mar. 12 at 2:52 PM
$PLSE We got a runner. HE KNOWS. Team Pulse
0 · Reply
bob2013
bob2013 Mar. 12 at 12:14 PM
$PLSE our mission to rigorously generate data and demonstrate the potential to improve patient outcomes and provide clinicians with more precise, tissue-sparing tools for minimally invasive treatment applications.” (HE KNOWS)!!!
0 · Reply
DARKP00L
DARKP00L Mar. 12 at 11:07 AM
$PLSE 07:06 on Mar. 12 2026 Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 12 at 11:00 AM
$PLSE Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
0 · Reply
TruthBroker2
TruthBroker2 Mar. 10 at 6:56 PM
$PLSE
0 · Reply
TruthBroker2
TruthBroker2 Mar. 10 at 3:50 PM
$PLSE Team Pulse
0 · Reply
BubbaHoTep
BubbaHoTep Mar. 9 at 2:44 PM
https://www.businesswire.com/news/home/20260309737760/en/ $PLSE
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 11:02 AM
$PLSE Pulse Biosciences announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy. The …
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 9 at 11:01 AM
$PLSE Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
0 · Reply
TruthBroker2
TruthBroker2 Mar. 6 at 3:26 PM
$PLSE I Believe 👍
0 · Reply
TruthBroker2
TruthBroker2 Mar. 5 at 7:25 PM
$PLSE Team Pulse
1 · Reply
bob2013
bob2013 Mar. 4 at 6:50 PM
$PLSE this is getting scary. This story just keeps on getting better! Once again, Paul’s presentation and recap was spot on. He’s moving with speed and focus reminding everyone that the #data drives everything ,and we’ve got it 250+ patents! Exquisite results are coming. not my words his! (HE KNOWS)!!!
1 · Reply
LeisureSuitLarry
LeisureSuitLarry Mar. 4 at 6:20 PM
$PLSE 👍🏻👍🏻
0 · Reply
TruthBroker2
TruthBroker2 Mar. 4 at 2:04 PM
$PLSE Team Pulse
1 · Reply
DARKP00L
DARKP00L Mar. 4 at 12:27 PM
$PLSE 07:11 on Mar. 04 2026 Pulse Biosciences Says nPulse Vybrance System To Be Featured In Podium And Product Theatre Presentations At North American Society For Interventional Thyroidology 2026 Meeting March 6-7 In Portland #tradeideas
0 · Reply
ravioli
ravioli Mar. 3 at 11:05 PM
$PLSE got some
0 · Reply
ravioli
ravioli Mar. 3 at 11:01 PM
$PLSE what happened here… absolutely crushed
0 · Reply
TruthBroker2
TruthBroker2 Feb. 25 at 6:26 PM
$PLSE 18.88 close.
1 · Reply